# Chronic-Progressive-EAE-Scaffolds-scRNAseq

Data and study design is publically available in the NIH GEO Database at Accession ID: [GSE287968](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287968)

1. C57/b6 mice are implanted with 13 mm PCL scaffolds on Day -14. 
2. C57/b6 mice are given adoptive transfer of MOG- or OVA-reactive T cells on Day 0.
3. Scaffolds are explanted at Day 7 (pre-symptomatic) and Day 9 (disease onset) for scRNAseq.

4. Data are in Data Den under Progressive EAE scRNAseq and code identifies each sample condition

Publications associated with this data:
1. Rad LM, Hughes KR, Wheeler SN, Decker JT, Orbach SM, Galvan A, Thornhill J, Griffin KV, Turkistani H, Urie RR, Irani DN, Shea LD, Morris AH. Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis. Proc Natl Acad Sci U S A. 2025 Feb 18;122(7):e2409852122. doi: [10.1073/pnas.2409852122](https://doi.org/10.1073/pnas.2409852122). Epub 2025 Feb 12. PMID: [39937858](https://pubmed.ncbi.nlm.nih.gov/39937858/); PMCID: PMC11848328.
